Ontology highlight
ABSTRACT: Background
In vitro data and early clinical results suggest that metformin has desirable antineoplastic effects and has a theoretical benefit on castration-resistant prostate cancer (CRPC).Objective
To determine whether the use of metformin would be associated with improved clinical outcomes and a reduction in the development of CRPC.Design, setting, and participants
Data from 2901 consecutive patients (157 metformin, 162 diabetic non-metformin, and 2582 nondiabetic) with localized prostate cancer treated with external-beam radiation therapy from 1992 to 2008 were collected from a single institution in the United States.Intervention
Use of metformin in localized prostate cancer.Outcome measurements and statistical analysis
Univariate and multivariate
SUBMITTER: Spratt DE
PROVIDER: S-EPMC4034673 | biostudies-literature | 2013 Apr
REPOSITORIES: biostudies-literature